Insight, China's Pharmaceutical Industry

Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism

Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced clinical trial approval from China’s National...

Company Drug

Huadong Medicine’s HDM2024 Wins NMPA Approval – EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors

Fineline Cube Mar 27, 2026

Huadong Medicine Co., Ltd. (SHE: 000963) announced clinical trial approval from China’s National Medical Products...

Company Drug

Biocytogen’s NEOK002 Wins FDA Approval for Phase I – EGFR/MUC1 Bispecific ADC Targets Solid Tumors

Fineline Cube Mar 27, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced that NEOK Bio, Inc., its...

Company Drug

Joincare Pharma’s JKN2404 Wins NMPA Approval for Asthma Trial – Next-Gen Inhaled Corticosteroid Targets Improved Safety Profile

Fineline Cube Mar 27, 2026

Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that JKN2404 inhalation suspension, a Category...

Company

Grand Pharma 2025 Revenue HKD 12.28B – Innovative Products Hit 50% of Sales, Radiopharma Soars 61%

Fineline Cube Mar 27, 2026

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) reported 2025 financial results, with revenue rising 5.5%...

Company Drug

Pulmongene’s PMG1015 Wins FDA Fast Track Designation – First-in-Class AREG Antibody Targets Idiopathic Pulmonary Fibrosis

Fineline Cube Mar 26, 2026

Pulmongene (Beijing) Ltd. announced that PMG1015 received Fast Track Designation (FTD) from the U.S. Food...

Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026

China’s State Council issued “Opinions on Accelerating the Establishment of a Long-Term Care Insurance System”,...

Company

Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%

Fineline Cube Mar 26, 2026

Simcere Pharmaceutical Group (HKG: 2096) reported 2025 financial results, with revenue rising 16.5% YoY to...

Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026

GlaxoSmithKline (GSK; NYSE: GSK) formed a strategic alliance with SPH Keyuan Trade, a China pharmaceutical...

Company Drug

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Fineline Cube Mar 26, 2026

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) announced National Medical Products Administration (NMPA) marketing approval for...

Others

Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%

Fineline Cube Mar 26, 2026

Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR...

Company Drug

United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 – Triple GLP-1/GIP/GCG Agonist Achieves 19.7% Weight Los

Fineline Cube Mar 26, 2026

Partners United Laboratories International Holdings Ltd (HKG: 3933) and Novo Nordisk (NYSE: NVO) announced positive...

Company

Ascentage Pharma 2025 Revenue RMB 574M – Olverembatinib NRDL Inclusion Drives 81% Growth, Lisaftoclax Launches

Fineline Cube Mar 26, 2026

Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) reported 2025 financial results, with revenue declining...

Company Deals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Fineline Cube Mar 26, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced a definitive agreement to acquire Terns Pharmaceuticals,...

Company Deals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Fineline Cube Mar 26, 2026

Daiichi Sankyo Co., Ltd. (TYO: 4568) announced a strategic partnership with Tempus AI, Inc., a...

Company

Hengrui Pharma 2025 Revenue RMB 31.6B – Innovative Drugs Drive 58% of Sales, Out-Licensing Hits RMB 3.4B

Fineline Cube Mar 26, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) reported 2025 annual results, with operating...

Company Deals

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Fineline Cube Mar 26, 2026

Thermo Fisher Scientific Inc. (NYSE: TMO) announced a strategic partnership with SHL Medical, a Switzerland-based...

Company

XtalPi Achieves First Profitability – AI Drug Discovery Revenue Surges 418% to RMB 538M, Global Sales Hit RMB 803M

Fineline Cube Mar 26, 2026

QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., reported 2025 financial results, achieving first annual...

Company

Everest Medicines Revenue Surges 142% to RMB 1.7B – Nefecon Becomes First Non-Oncology Drug to Hit RMB 1B in First NRDL Year

Fineline Cube Mar 26, 2026

Everest Medicines (HKG: 1952) reported 2024 financial results, with revenue skyrocketing 142% YoY to RMB...

Company Drug

CStone’s Sugemalimab Wins ESMO [I, A] Recommendation – PD-L1 Inhibitor Targets Stage III NSCLC Consolidation Therapy in Europe

Fineline Cube Mar 26, 2026

CStone Pharmaceuticals (HKG: 2616) announced that sugemalimab received a class recommendation in the...

Insight, China's Pharmaceutical Industry

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism

Huadong Medicine’s HDM2024 Wins NMPA Approval – EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors

Biocytogen’s NEOK002 Wins FDA Approval for Phase I – EGFR/MUC1 Bispecific ADC Targets Solid Tumors

Joincare Pharma’s JKN2404 Wins NMPA Approval for Asthma Trial – Next-Gen Inhaled Corticosteroid Targets Improved Safety Profile

Grand Pharma 2025 Revenue HKD 12.28B – Innovative Products Hit 50% of Sales, Radiopharma Soars 61%

Pulmongene’s PMG1015 Wins FDA Fast Track Designation – First-in-Class AREG Antibody Targets Idiopathic Pulmonary Fibrosis

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%

United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 – Triple GLP-1/GIP/GCG Agonist Achieves 19.7% Weight Los

Ascentage Pharma 2025 Revenue RMB 574M – Olverembatinib NRDL Inclusion Drives 81% Growth, Lisaftoclax Launches

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Hengrui Pharma 2025 Revenue RMB 31.6B – Innovative Drugs Drive 58% of Sales, Out-Licensing Hits RMB 3.4B

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

XtalPi Achieves First Profitability – AI Drug Discovery Revenue Surges 418% to RMB 538M, Global Sales Hit RMB 803M

Everest Medicines Revenue Surges 142% to RMB 1.7B – Nefecon Becomes First Non-Oncology Drug to Hit RMB 1B in First NRDL Year

CStone’s Sugemalimab Wins ESMO [I, A] Recommendation – PD-L1 Inhibitor Targets Stage III NSCLC Consolidation Therapy in Europe

You Missed

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology